Disease · MONDO_0005315
bone fracture
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. bone fracture. Diseases, record MONDO_0005315. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005315
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- Bone Fractures, Bone, Broken, Bones, Broken, Broken Bone, Broken Bones, Fracture, Bone, Fractures, Bone, fracture, fracture of bone, fracture(s)
- Open Targets
- Highest stage of its drugs
- Approval, for 5 of its 27 drugs, from EMA Human Drugs and PMDA
- Open Targets
Drugs27
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| TERIPARATIDE | CHEMBL525610 | Protein | Approval | PMDA | 6 | 4 | 4 | Drugs and targets |
| ZOLEDRONIC ACID | CHEMBL4303669 | Small molecule | Approval | EMA Human Drugs | 7 | 1 | 1 | Drugs and targets |
| IBANDRONIC ACID | CHEMBL997 | Small molecule | Approval | EMA Human Drugs | 4 | 0 | 0 | Drugs and targets |
| ROMOSOZUMAB | CHEMBL2107874 | Antibody | Approval | PMDA | 1 | 0 | 0 | Drugs and targets |
| TERIPARATIDE ACETATE | CHEMBL1201549 | Protein | Approval | PMDA | 1 | 0 | 0 | Drugs and targets |
| KETAMINE | CHEMBL742 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ALENDRONIC ACID | CHEMBL870 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MIDAZOLAM | CHEMBL655 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MORPHINE | CHEMBL70 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RISEDRONIC ACID | CHEMBL923 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 27
See all 27 drugsTargets42
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| FDPS | Farnesyl pyrophosphate synthase | 4 | Farnesyl diphosphate synthase inhibitor | Approval | https://conductscience.org/library/genes/2224 | Drugs and targets |
| PTH1R | Parathyroid hormone/parathyroid hormone-related peptide receptor | 4 | Parathyroid hormone receptor agonist | Approval | https://conductscience.org/library/genes/5745 | Drugs and targets |
| AR | Androgen receptor | 2 | Androgen Receptor antagonist | Unknown | https://conductscience.org/library/genes/367 | Drugs and targets |
| VDR | Vitamin D3 receptor | 2 | Vitamin D receptor agonist | Phase 2 | https://conductscience.org/library/genes/7421 | Drugs and targets |
| ADRA2A | Adrenergic receptor alpha-2 | 1 | Adrenergic receptor alpha-2 agonist | Phase 2/3 | https://conductscience.org/library/genes/150 | Drugs and targets |
| ADRA2B | Adrenergic receptor alpha-2 | 1 | Adrenergic receptor alpha-2 agonist | Phase 2/3 | https://conductscience.org/library/genes/151 | Drugs and targets |
| ADRA2C | Adrenergic receptor alpha-2 | 1 | Adrenergic receptor alpha-2 agonist | Phase 2/3 | https://conductscience.org/library/genes/152 | Drugs and targets |
| CYP17A1 | Steroid 17-alpha-hydroxylase/17,20 lyase | 1 | Cytochrome P450 17A1 inhibitor | Unknown | https://conductscience.org/library/genes/1586 | Drugs and targets |
| GABRA1 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2554 | Drugs and targets |
| GABRA2 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2555 | Drugs and targets |
1 to 10 of 42
See all 42 targetsTrials19
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01512446 | Comparison of the Effect of an Ongoing Treatment With Alendronate or a Drug Holiday on the Fracture Risk in Osteoporotic Patients With Bisphosphonate Long Term Therapy | Phase 3 | 436 | 2019-01-17 | Osteoporosis | ALENDRONIC ACID | Its record names the disease | ClinicalTrials.gov |
| NCT00503399 | Comparison of the Effects of 2 Drugs on Lumbar Spine Volumetric BMD in Men With Glucocorticoid-Induced Osteoporosis | Phase 3 | 92 | 2011-11-08 | Osteoporosis | RISEDRONIC ACID, TERIPARATIDE | Its record names the disease | ClinicalTrials.gov |
| NCT04760782 | PTH Analog Type II Odontoid Fracture | Phase 2 | 22 | 2024-09-19 | Odontoid Fracture | ABALOPARATIDE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT03960554 | The Effects of 12-months of Denosumab on Bone Density in Prevalent Kidney Transplant Recipients | Phase 2 | 8 | 2024-07-25 | Osteoporosis, Renal Osteodystrophy, Kidney Transplant; Complications | DENOSUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04256993 | PRECISE, a Study to Gather More Information About Bone Fractures and Survival in Castration-resistant PRostate Cancer (CRPC) patiEnts Treated With Radium-223 in Routine Clinical practIce in SwedEn | 1,434 | Metastatic Castration-Resistant Prostate Cancer | RADIUM RA 223 DICHLORIDE | Its record names the disease | ClinicalTrials.gov | ||
| NCT04195256 | Intranasal Dexmedetomidine Plus Ketamine for Procedural Sedation | Phase 2/3 | 400 | Fracture, Dislocation | DEXMEDETOMIDINE, KETAMINE | Its record names the disease | ClinicalTrials.gov | |
| NCT03896984 | Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo). | 346 | Metastatic Castration-resistant Prostate Cancer (mCRPC) | ABIRATERONE, ENZALUTAMIDE, RADIUM RA-223 | Its record names the disease | ClinicalTrials.gov | ||
| NCT02999022 | Lithium for Fracture Treatment: a Double Blind Randomized Controlled Trial (LiFT) | Phase 2 | 160 | Fractures | LACTOSE, ANHYDROUS, LITHIUM CARBONATE | Its record names the disease | ClinicalTrials.gov | |
| NCT04196855 | Study of Teriparatide in Stress Fracture Healing | Phase 3 | 136 | Stress Fracture, Parathyroid Hormone | TERIPARATIDE | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov | |
| NCT05058443 | Denosumab and Osteoporotic Vertebral Compression Fracture | Phase 2/3 | 90 | Osteoporotic Vertebral Compression Fracture | DENOSUMAB | Open Targets' reading of its record | ClinicalTrials.gov |
1 to 10 of 19
See all 19 trialsComparisons in its trials8
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Alendronate vs Placebo: Combination of New Osteoporotic Fractures and Deaths | 5 of 215 | 7 of 221 | 436 | NCT01512446 | Trial comparisons |
| Alendronate vs Placebo: Mortality | 0 of 215 | 2 of 221 | 436 | NCT01512446 | Trial comparisons |
| Alendronate vs Placebo: serious adverse events | 31 of 188 | 38 of 197 | 385 | NCT01512446 | Trial comparisons |
| Teriparatide vs Risedronate: serious adverse events | 13 of 45 | 22 of 47 | 92 | NCT00503399 | Trial comparisons |
| Active Drug vs Placebo: deaths from any cause | 0 of 4 | 0 of 4 | 8 | NCT03960554 | Trial comparisons |
| Active Drug vs Placebo: serious adverse events | 0 of 4 | 0 of 4 | 8 | NCT03960554 | Trial comparisons |
| Treatment Group vs Historical Control Group: deaths from any cause | 1 of 5 | 0 of 2 | 7 | NCT04760782 | Trial comparisons |
| Treatment Group vs Historical Control Group: serious adverse events | 1 of 5 | 0 of 2 | 7 | NCT04760782 | Trial comparisons |
Papers from its trials12
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005315
GET https://conductscience.org/api/diseases/v1/MONDO_0005315/drugs?page=2